Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.

Wu X, Yeerna H, Goto Y, Ando T, Wu VH, Zhang X, Wang Z, Amornphimoltham P, Murphy AN, Tamayo P, Chen Q, Lippman SM, Gutkind JS.

Cancer Res. 2019 Sep 1;79(17):4360-4370. doi: 10.1158/0008-5472.CAN-18-3525. Epub 2019 Jul 10.

PMID:
31292160
2.

Metformin Clinical Trial in HPV+ and HPV- Head and Neck Squamous Cell Carcinoma: Impact on Cancer Cell Apoptosis and Immune Infiltrate.

Curry JM, Johnson J, Mollaee M, Tassone P, Amin D, Knops A, Whitaker-Menezes D, Mahoney MG, South A, Rodeck U, Zhan T, Harshyne L, Philp N, Luginbuhl A, Cognetti D, Tuluc M, Martinez-Outschoorn U.

Front Oncol. 2018 Oct 11;8:436. doi: 10.3389/fonc.2018.00436. eCollection 2018.

3.

Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin.

Patel H, Younis RH, Ord RA, Basile JR, Schneider A.

J Oral Pathol Med. 2013 Mar;42(3):250-6. doi: 10.1111/j.1600-0714.2012.01196.x. Epub 2012 Aug 3.

PMID:
22861817
4.

Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.

Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R.

Cell Cycle. 2012 Apr 1;11(7):1374-82. doi: 10.4161/cc.19798. Epub 2012 Apr 1.

5.

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis.

Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, Chandel NS.

Elife. 2014 May 13;3:e02242. doi: 10.7554/eLife.02242.

6.

Metformin Results in Diametrically Opposed Effects by Targeting Non-Stem Cancer Cells but Protecting Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma.

Kuo SZ, Honda CO, Li WT, Honda TK, Kim E, Altuna X, Abhold E, Wang-Rodriguez J, Ongkeko WM.

Int J Mol Sci. 2019 Jan 7;20(1). pii: E193. doi: 10.3390/ijms20010193.

7.

Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1.

Liu K, Du S, Gao P, Zheng J.

J Cancer. 2019 Jul 10;10(18):4196-4207. doi: 10.7150/jca.34145. eCollection 2019.

8.

MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.

Sun Z, Hu W, Xu J, Kaufmann AM, Albers AE.

Int J Oncol. 2015 Oct;47(4):1339-50. doi: 10.3892/ijo.2015.3142. Epub 2015 Aug 31.

PMID:
26323460
9.

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.

Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG, Gutkind JS.

Oncotarget. 2014 Oct 15;5(19):8906-23.

10.

Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma.

Zhang M, Kumar B, Piao L, Xie X, Schmitt A, Arradaza N, Cippola M, Old M, Agrawal A, Ozer E, Schuller DE, Teknos TN, Pan Q.

Cancer. 2014 Apr 1;120(7):992-1001. doi: 10.1002/cncr.28538. Epub 2013 Dec 30.

11.

Metformin effects on FOXP3+ and CD8+ T cell infiltrates of head and neck squamous cell carcinoma.

Amin D, Richa T, Mollaee M, Zhan T, Tassone P, Johnson J, Luginbuhl A, Cognetti D, Martinez-Outschoorn U, Stapp R, Solomides C, Rodeck U, Curry J.

Laryngoscope. 2019 Oct 8. doi: 10.1002/lary.28336. [Epub ahead of print]

PMID:
31593308
12.

CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.

Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF.

PLoS One. 2011;6(11):e28053. doi: 10.1371/journal.pone.0028053. Epub 2011 Nov 28.

13.

Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.

Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Gao D, Tan AC, Serracino H, Vasiliou V, Roop DR, Wang XJ, Jimeno A.

J Natl Cancer Inst. 2016 Sep 15;109(1). doi: 10.1093/jnci/djw189. Print 2017 Jan.

14.

Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.

Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA.

Genome Med. 2018 Jul 20;10(1):54. doi: 10.1186/s13073-018-0569-7.

15.

MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells.

Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, Tseng LM, Chu PY, Lu KH, Chang KW, Kao SY, Chiou SH.

J Pathol. 2011 Mar;223(4):482-95. doi: 10.1002/path.2826. Epub 2011 Jan 5.

PMID:
21294122
16.

Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.

Verma A, Rich LJ, Vincent-Chong VK, Seshadri M.

J Oral Pathol Med. 2018 May;47(5):484-491. doi: 10.1111/jop.12705. Epub 2018 Apr 10.

17.

Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.

Koshizuka K, Hanazawa T, Kikkawa N, Katada K, Okato A, Arai T, Idichi T, Osako Y, Okamoto Y, Seki N.

Auris Nasus Larynx. 2018 Aug;45(4):854-865. doi: 10.1016/j.anl.2017.11.019. Epub 2017 Dec 9.

PMID:
29233721
18.
19.

TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.

Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N.

Cancer. 2017 May 15;123(10):1778-1790. doi: 10.1002/cncr.30570. Epub 2017 Mar 13.

20.

Let-7c inhibits migration and epithelial-mesenchymal transition in head and neck squamous cell carcinoma by targeting IGF1R and HMGA2.

Hou B, Ishinaga H, Midorikawa K, Nakamura S, Hiraku Y, Oikawa S, Ma N, Takeuchi K, Murata M.

Oncotarget. 2018 Jan 2;9(10):8927-8940. doi: 10.18632/oncotarget.23826. eCollection 2018 Feb 6.

Supplemental Content

Support Center